Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HDM 2005

Next Previous
Drug Profile

HDM 2005

Alternative Names: HDM-2005

Latest Information Update: 20 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hangzhou Zhongmei Huadong Pharmaceutical
  • Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunotoxins
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mantle-cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Diffuse large B cell lymphoma
  • Phase I B-cell lymphoma; Mantle-cell lymphoma; Solid tumours

Most Recent Events

  • 20 Jul 2026 Hangzhou Zhongmei Huadong Pharmaceutical plans a phase Ib/III trial for Mantle cell lymphoma (Combination therapy, Second-line therapy or greater) (IV) (NCT07697339)
  • 06 Dec 2025 Efficacy and adverse events data from a phase I trial in B-Cell Lymphoma presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
  • 05 Sep 2025 Efficacy and adverse events data from a phase I trial in Mantle cell lymphoma, Diffuse large B-cell lymphoma, B-cell non-Hodgkin lymphoma or classical Hodgkin lymphoma released by Hangzhou Zhongmei Huadong Pharmaceutical

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top